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Dendritic  cells  (DC)  develop  from  hematopoietic  stem  cells,  which  is guided  by instructive  signals  through
cytokines.  DC  development  progresses  from  multipotent  progenitors  (MPP)  via common  DC  progenitors
(CDP)  into  DC.  Flt3 ligand  (Flt3L)  signaling  via  the  Flt3/Stat3  pathway  is  of pivotal  importance  for  DC
development  under  steady  state  conditions.  Additional  factors  produced  during  steady  state  or  inﬂam-
mation,  such as  TGF-1  or  GM-CSF,  also  inﬂuence  the  differentiation  potential  of  MPP and  CDP. Here,  we
studied  how  gp130,  GM-CSF  and  TGF-1  signaling  inﬂuence  DC lineage  commitment  from  MPP  to  CDP
and  further  into  DC.  We  observed  that activation  of  gp130  signaling  promotes  expansion  of  MPP. Addi-
tionally,  gp130  signaling  inhibited  Flt3L-driven  DC  differentiation,  but  had little effect on  GM-CSF-driven
DC  development.  The  inﬂammatory  cytokine  GM-CSF  induces  differentiation  of MPP into  inﬂammatory
DC  and  blocks  steady  state  DC development.  Global  transcriptome  analysis  revealed  a GM-CSF-drivenineage commitment
GF-1
p130
M-CSF
gene  expression  repertoire  that  primes  MPP  for differentiation  into  inﬂammatory  DC.  Finally,  TGF-1
induces  expression  of  DC-lineage  afﬁliated  genes  in MPP,  including  Flt3,  Irf-4  and  Irf-8.  Under  inﬂam-
matory  conditions,  however,  the  effect  of  TGF-1  is  altered:  Flt3  is  not upregulated,  indicating  that  an
inﬂammatory  environment  inhibits  steady  state  DC  development.  Altogether,  our data  indicate  that  dis-
tinct  cytokine  signals  produced  during  steady  state  or inﬂammation  have  a  different  outcome  on  DC
 diffelineage  commitment  and
ntroduction
Dendritic cells (DC) represent a diverse collection of hematopoi-
tic cells, which are specialized in antigen presentation and
nduction of effector T-cell responses (Reis e Sousa, 2006; Steinman
nd Banchereau, 2007). DC have been classiﬁed into different
ubsets based on their location, function and origin. In gen-
ral, DC can be subdivided into lymphoid tissue DC and in
on-lymphoid tissue DC (Merad and Manz, 2009; Shortman
nd Naik, 2007). Splenic DC for example include plasmacytoid
C (pDC), which produce vast amounts of type I interfer-
ns upon viral infection, and lymphoid tissue-resident DC or
lassical DC (cDC). Non-lymphoid tissue DC are also referred
o as migratory or tissue DC and are present in peripheral
issue. There they continuously capture and process antigens
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upon which they migrate to draining lymph nodes for antigen
presentation.
All cells of the hematopoietic system, including DC, have to be
repopulated continuously from bone marrow-derived stem and
progenitor cells. Due to the heterogeneity of DC,  the exact origin of
different DC subsets and their developmental relationship remains
under investigation. The understanding that the Flt3/STAT3 path-
way is of pivotal importance for steady state DC development
(Laouar et al., 2003; McKenna et al., 2000; Onai et al., 2006),
lead to the identiﬁcation of DC committed precursors, which all
express the receptor tyrosine kinase Flt3 (Auffray et al., 2009; Naik
et al., 2006, 2007; Onai et al., 2007). These precursors include
the macrophage/DC progenitor (MDP) and the common DC pro-
genitor (CDP), which reside in the bone marrow and give rise to
all lymphoid tissue DC subsets, and pre-DC which have lost pDC
development potential. Adoptive transfer experiments revealed
the hierarchy between these different progenitor cells of the DC
lineage (Liu et al., 2009). MDP  give rise to CDP, which then
generate pDC and pre-DC. pre-DC leave the bone marrow and
Open access under CC BY-NC-ND license.differentiate into cDC and into speciﬁc subsets of non-lymphoid
tissue DC.
Lineage commitment during hematopoiesis is guided by inter-
nal and external factors that direct differentiation of stem and
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rogenitor cells into speciﬁc lineages. Cytokine signaling has an
nstructive function in cell fate decision and it was shown that
xternal factors can redirect lineage-committed precursors into a
ifferent compartment (Kondo et al., 2000; Onai et al., 2006). Recent
tudies indicate that also microbial components and inﬂammatory
ediators inﬂuence stem and progenitor cells (Belyaev et al., 2010;
agai et al., 2006), providing evidence that lineage determination
s altered under inﬂammatory conditions.
Several growth factors have been identiﬁed which support DC
evelopment. Frequently, DC are generated in vitro by culturing
one marrow cells or monocytes with GM-CSF (Inaba et al., 1992;
allusto and Lanzavecchia, 1994). However, DC cultured with GM-
SF (GM-DC) do not resemble steady state cDC, but rather represent
C which develop under inﬂammatory conditions (Geissmann
t al., 2010; Shortman and Naik, 2007). GM-CSF/STAT5 signaling
as found to even block pDC development (Esashi et al., 2008).
n steady state, monocytes do not constitute DC precursors for
ymphoid organ DC (Naik et al., 2006; Varol et al., 2007). DC gener-
ted in vitro with the Flt3 ligand (Flt3L), however, closely resemble
teady state lymphoid organ DC (Brawand et al., 2002; Naik et al.,
005). Moreover, Flt3L is the key growth factor for establishment of
he DC lineage in vivo, including MDP  and CDP (Kingston et al., 2009;
cKenna et al., 2000). The contribution of GM-CSF to steady state
C development is limited, but GM-CSF seems to have a synergis-
ic role with Flt3L in the maintenance of DC progenitors (Kingston
t al., 2009).
Recently we described a two-step culture system that faith-
ully reproduces steady state DC development in vitro (Felker et al.,
010). In the ﬁrst step, bone marrow cells are ampliﬁed with stem
ell factor (SCF), Flt3L, IL-6/soluble IL-6R fusion protein (hyper-IL-
) and insulin growth factor-1 (IGF-1), four cytokines that induce
elf-renewal of multipotent progenitors (MPP) and their progres-
ion to CDP. In the second step, CDP can be differentiated with Flt3L
nto pDC and cDC, or with GM-CSF into GM-DC.
Although in vitro culture systems are simpliﬁcations of the com-
lex micro-environment in bone marrow, they provide a means
o dissect molecular mechanisms by which individual growth or
ranscription factors inﬂuence DC lineage commitment and differ-
ntiation. As stem and progenitor cell populations in bone marrow
re scarce, generation of large numbers of MPP, CDP and DC in vitro
llows analyses which are otherwise difﬁcult. Likewise, we could
how through genome wide microarray analysis that CDP possess
 DC-primed transcription proﬁle (Felker et al., 2010). Moreover,
GF-1 appeared to accelerate DC development from CDP and
iased subset speciﬁcation towards cDC by upregulating expres-
ion of cDC speciﬁc transcription factors.
In general, transcription factors are instructive factors deter-
ining cell fate and lineage commitment during hematopoiesis.
uch of our understanding about the role of transcription factors
n DC development originates from mouse models with speciﬁc
eletion of genes important for DC development (Geissmann et al.,
010; Merad and Manz, 2009; Zenke and Hieronymus, 2006). Some
ranscription factors, like STAT3 and Gﬁ-1, are important for DC
ifferentiation in general, as all lymphoid organ DC subsets are
educed in the respective knockout mouse models (Laouar et al.,
003; Rathinam et al., 2005). Other transcription factors are impor-
ant for development of speciﬁc DC subsets. pDC generation for
xample depends on expression of interferon regulatory factor 8
Irf-8), Irf-4, E2-2 and Spi-B (Cisse et al., 2008; Schiavoni et al., 2002;
chotte et al., 2004; Tamura et al., 2005). CD8+ cDC subset devel-
pment on the other hand is strongly reduced in the absence of Irf-8,
d2 and Batf3, but unaffected by lack of E2-2 (Hacker et al., 2003;
ildner et al., 2008; Schiavoni et al., 2002). Together these observa-
ions depict a transcription factor network in which the expression
evels of the various factors guide lineage commitment and subset
peciﬁcation.ell Biology 91 (2012) 515– 523
Here we have used the two-step in vitro culture system
described before (Felker et al., 2010) to study the impact of further
cytokine signaling pathways on DC development. We  describe that
activation of hyper-IL-6/gp130 signaling interferes with MPP  to
CDP progression as well as Flt3L-driven DC differentiation. Inﬂam-
matory signals affect the developmental potential of stem and
progenitor cells. We  now determined how MPP  might get primed
by GM-CSF/STAT5 signaling to develop into GM-DC and to block
steady state DC differentiation. Finally, we analyzed the inﬂuence
of TGF-1 on MPP. TGF-1 is important for Langerhans cell (LC)
development (Borkowski et al., 1996; Strobl and Knapp, 1999)
and accelerates DC differentiation from CDP (Felker et al., 2010).
TGF-1/Smad signaling induces Id2, Irf-8 and Pu.1, transcription
factors important for development of LC as well as other DC sub-
sets (Hacker et al., 2003; Heinz et al., 2006; Ju et al., 2007). Yet,
the impact of TGF-1 on DC lineage commitment in MPP  is so far
unknown. We  show here that TGF-1 upregulates Flt3 and Irf-8
which suggests that TGF-1 induces DC commitment in MPP.
Materials and methods
Mice
C57BL/6 mice were maintained under speciﬁc pathogen-free
conditions at the central animal facility of RWTH Aachen University
Hospital, Aachen, Germany. All animal experiments were approved
by local authorities in compliance with German animal protection
law.
Cell culture and colony formation assay
Mouse bone marrow cells were cultured as described (Felker
et al., 2010). Brieﬂy, cells were ampliﬁed by culturing with stem cell
factor (SCF, 30 U/ml; PeproTech, Rocky Hill, NJ), Flt3 ligand (Flt3L,
25 ng/ml; PeproTech), long-range insulin-like growth factor-1 (IGF-
1, 40 ng/ml; Sigma-Aldrich, St. Louis, MO)  and IL-6/soluble IL-6R
fusion protein (hyper-IL-6, 25 ng/ml) (Fischer et al., 1997). After
7–8 days of ampliﬁcation, cells were used for further experiments.
Ampliﬁcation of GM-MPP that includes culture in the presence
of GM-CSF was performed accordingly as described (Hieronymus
et al., 2005). TGF-1 (R&D Systems, Minneapolis, MN)  was used at
2.5 ng/ml for long-term treatments.
For DC differentiation, ampliﬁed progenitors were cultured with
Flt3L (50 ng/ml) or GM-CSF (200 U/ml; PeproTech). Cells were used
for analysis after 6–8 days of differentiation. TNF- treatment
(100 ng/ml; PeproTech) was  performed in some experiments for
further maturation of differentiated DC. Alternatively, DC were
generated with Flt3L from bone marrow cells without initial ampli-
ﬁcation by culture for 8–10 days (Naik et al., 2005).
For colony forming assays, 2500 cells were seeded in methylcel-
lulose containing insulin, transferrin, erythropoietin (Epo), SCF, IL-3
and IL-6 (MethoCult GF M3434, StemCell Technologies, Vancouver,
Canada). Colony formation was analyzed after 3 days.
Cell numbers were determined with an electronic cell counter
device (Casy1, Schärfe Systems, Reutlingen, Germany).
Flow cytometry and cell sorting
Surface marker expression on in vitro cultured cells by ﬂow
cytometry and cell sorting of ampliﬁed MPP  was performed as
described (Felker et al., 2010). Brieﬂy, ampliﬁed progenitors were
deprived of growth factors for 1.5 h and subsequently stained for
Flt3, c-kit, CD115, CD127 and CD11c. MPP  were sorted as c-kithi
Flt3−/lo CD127− CD11c− cells with a FACSAria device (BD Bio-
science, San Jose, CA). Cells were immediately put back in culture
al of Cell Biology 91 (2012) 515– 523 517
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Fig. 1. (A) Bone marrow cells were cultured with SCF, Flt3L, IGF-1 and hyper-IL-6
for  7–8 days with 25 ng/ml hyper-IL-6, and then for an additional 4 days at normal
and increased hyper-IL-6 concentration (25 and 100 ng/ml, respectively). Cells were
stained for c-kit, Flt3, Gr-1 and CD115 and analyzed by ﬂow cytometry. MPP  and CDP
were deﬁned as Gr-1− c-kithi Flt3−/lo and Gr-1− c-kitlo Flt3+ CD115+, respectively.
(B)  Bone marrow cells were cultured with SCF, Flt3L, IGF-1 and hyper-IL-6 for 14
days with increasing concentrations of hyper-IL-6 as indicated and analyzed for
MPP  and CDP by ﬂow cytometry as in (A). Proportion of MPP  and CDP is depicted in
percent (mean values of 3 experiments). (C) Ampliﬁed progenitors at day 8 of culture
were deprived of growth factors for 6 h and stimulated for 15 min  with increasing
concentrations of hyper-IL-6. STAT3 phosphorylation (p-STAT3) and total STAT3K.M. Seré et al. / European Journ
nder ampliﬁcation conditions and treated with TGF-1 (10 ng/ml,
&D Systems) for various time intervals.
NA isolation, reverse transcription and quantitative PCR
RNA isolation and cDNA synthesis was performed as described
reviously (Felker et al., 2010). Quantitative PCR was performed
ith 50 ng cDNA with SYBR-green ﬂuorescence (Fast SYBR
reen Master Mix, Applied Biosystems, Foster city, CA) using
 StepOnePlusTM Real Time PCR System (Applied Biosystems).
APDH was used for normalization. Data analysis was  performed
ith the StepOneTM Software v2.1 (Applied Biosystems).
NA microarray analysis
RNA from GM-MPP and GM-DC was prepared and subjected
o microarray analysis as in Felker et al. (2010).  Hybridization
as done on Affymetrix Mouse Genome 430 v2.0 (Affymetrix,
anta Clara, CA). Data sets were submitted to the Gene Expression
mnibus database (www.ncbi.nlm.nih.gov/geo; accession number
SE29241). Data sets of MPP, CDP, cDC and pDC (GSE22432) were
rom Felker et al. (2010).
Raw microarray data were normalized with the RMA  algo-
ithm implemented in R/Bioconductor. To minimize batch effects,
ormalized data were further corrected with the ComBat algo-
ithm (Johnson et al., 2007). Principal component analysis (PCA)
as done by prcomp in R package stats. Hierarchical clustering
as calculated using the Pearson correlation coefﬁcient and the
verage linkage method. Differentially expressed genes were deter-
ined by the limma moderated T-test with deﬁned criteria (a
old change >2 and p values <0.01). Raw p values were adjusted
y Benjamini and Hochberg’s method (Benjamini and Hochberg,
995).
DS-PAGE and Western blotting
For analysis of STAT3 activation, ampliﬁed progenitors were
epleted of growth factors for 6 h and subsequently stimulated
ith hyper-IL-6 (0.1–1 g/ml) for 15 min. Cell lysis, SDS-PAGE and
estern blotting were performed as described before (Ju et al.,
007). The following antibodies were used: monoclonal mouse
nti-STAT3 (BD Bioscience) and monoclonal mouse anti-phospho-
TAT3 (3E2; Cell Signaling, Beverly, MA). Secondary peroxidase
onjugated sheep anti-mouse was from Amersham (GE Health-
are, Buckinghamshire, UK). Membranes were incubated with ECL
eagent (SuperSignal West Dura, Thermo Scientiﬁc, Rockford, IL)
nd exposed to X-ray ﬁlm (CL-XPosure Film, Thermo Scientiﬁc) for
etection.
esults and discussion
p130 signaling promotes self-renewal of MPP  and blocks
lt3L-induced DC differentiation
MPP  and CDP were obtained from bone marrow cells in vitro
ith SCF, Flt3L, IGF-1 and hyper-IL-6, as recently described (Felker
t al., 2010). After 1 week of culture, MPP  and CDP were charac-
erized as c-kithi Flt3−/lo cells and c-kitlo Flt3+ cells, respectively
Fig. 1A, left panel). gp130 signaling contributes to expansion
f hematopoietic stem cells in vitro and in vivo (Audet et al.,
001; Peters et al., 1997; Sui et al., 1995) and hyper-IL-6 is potent stimulator of gp130 signaling (Fischer et al., 1997).
ere we determined how hyper-IL-6 impacts on growth and
evelopment of MPP  and CDP. We  observed that at a high hyper-
L-6 concentration (100 ng/ml) MPP  development was favored atexpression was  assessed by Western blot analysis.
the expense of CDP (Fig. 1B). At a low hyper-IL-6 concentra-
tion (6.25 ng/ml) MPP  were reduced by almost 50% compared
to standard concentrations of hyper-IL-6 (25 ng/ml). At very low
concentrations or in the absence of hyper-IL-6, cells progressed
further into DC (data not shown). Thus, during proliferation of
bone marrow cells in the four-factor cocktail, hyper-IL-6 pro-
motes the establishment of MPP  and blocks the development of
CDP.
Next we  analyzed if hyper-IL-6 had a similar effect on the
maintenance of MPP  and CDP. Therefore, MPP/CDP cultures were
established under standard conditions. Subsequently, cells were
maintained proliferating at 25 ng/ml or at 100 ng/ml hyper-IL-6
and analyzed by ﬂow cytometry 4 days later. A high concen-
tration of hyper-IL-6 antagonized the maintenance of the CDP
population, leading to a prominent MPP  population in the culture
(Fig. 1A).
Finally, hyper-IL-6 is known to activate STAT3 signaling
(Rakemann et al., 1999). Therefore we tested if in cultured pro-
genitors, hyper-IL-6 signaling occurred via the same pathway.
Indeed, stimulation of MPP/CDP culture with hyper-IL-6 induced
518 K.M. Seré et al. / European Journal of Cell Biology 91 (2012) 515– 523
Fig. 2. Steady state but not inﬂammatory DC development is affected by gp130 signaling. (A) In vitro ampliﬁed progenitors were induced to differentiate into DC by Flt3L
in  the presence and absence of hyper-IL-6 (25 ng/ml). Cells were analyzed by ﬂow cytometry after 6 days of differentiation. CD11c expression was used as a DC marker. (B)
Freshly isolated bone marrow cells were put in culture with Flt3L or Flt3L and hyper-IL-6 (25 ng/ml). After 8 days of culture, cell numbers were determined and are depicted
(mean  values ± SD of 3 experiments). (C and D) In vitro ampliﬁed progenitors were differentiated into GM-DC with GM-CSF in the presence or absence of hyper-IL-6. (C) DC
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sevelopment was assessed by ﬂow cytometry and CD11c and MHC II expression. (
gray histograms). White histograms represent isotype controls.
trong STAT3 phosphorylation, as shown by Western blotting
Fig. 1C).
Hyper-IL-6 clearly blocked development of MPP  into CDP, thus
e hypothesized that hyper-IL-6 might also affect DC differen-
iation. MPP/CDP cultures were induced to differentiate into DC
ith Flt3L only. After 6 days of differentiation, more than 80% of
iable cells expressed high levels of the DC marker CD11c (Fig. 2A,
eft panel). When hyper-IL-6 was added during differentiation, DC
evelopment was blocked and no CD11chi cell population was
etected (Fig. 2A, right panel). In the presence of hyper-IL-6 cells
ather acquired a phenotype of myelomonocytic cells expressing
-CSF receptor CD115 and Gr-1.
Since MPP/CDP were obtained in the presence of four cytokines,
ncluding hyper-IL-6, it can be reasoned that during these 7 days
f in vitro culture, factor-dependent cells were selected which
re highly responsive to hyper-IL-6. Therefore, the experiment
as repeated with freshly isolated bone marrow cells which were
ifferentiated into DC with Flt3L in the presence or absence of
yper-IL-6. Also in this setting, addition of hyper-IL-6 to Flt3L inhib-
ted the development of CD11chi DC. Moreover, the combination
f hyper-IL-6 and Flt3L caused high cell proliferation resulting in
lmost 10-fold higher cell numbers compared to Flt3L only (Fig. 2B).
his proliferative effect was dependent on the presence of both
rowth factors, as hyper-IL-6 alone did not lead to substantial cell
urvival or proliferation (data not shown).11c+ MHC  II+ cells were gated and further analyzed for CD40 and CD80 expression
Next, we determined whether differentiation of DC using GM-
CSF (GM-DC) was  affected by hyper-IL-6. Therefore, MPP/CDP
culture was differentiated into DC with GM-CSF in the presence
or absence of hyper-IL-6 for 6 days. Flow cytometry showed that
the majority of cells expressed CD11c at high levels, while MHC  II
expression was heterogeneous (Fig. 2C, left panel). Interestingly, in
contrast to Flt3L driven differentiation, GM-CSF driven DC devel-
opment was hardly affected by hyper-IL-6 (Fig. 2C, right panel).
The CD11chi cells generated in the presence or absence of hyper-
IL-6 showed similar levels of MHC  II, CD40 and CD80 expression
(Fig. 2C and D).
Together, these results show that gp130 signaling promotes
MPP  expansion, which is in agreement with previous data (Audet
et al., 2001; Peters et al., 1997; Sui et al., 1995), and interferes with
steady state DC development. Thus, an optimal concentration of
hyper-IL-6 in MPP/CDP cultures is essential to maintain the bal-
ance between proliferation on the one hand and commitment to DC
lineage on the other hand. Flt3/STAT3 signaling is the central path-
way in steady state DC development (Laouar et al., 2003; McKenna
et al., 2000; Onai et al., 2006) and hyper-IL-6/gp130 acts as a potent
STAT3 activator too. However, a combination of Flt3L and hyper-IL-
6 had no synergistic inﬂuence on DC development. The molecular
mechanism of Flt3L/hyper-IL-6 antagonism is not clear, but addi-
tional signaling pathways activated or blocked by either of the
cytokines might be involved. GM-CSF-driven DC development is
al of Cell Biology 91 (2012) 515– 523 519
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Fig. 3. Global gene expression analysis of MPP  and DC grown under steady state
and inﬂammatory conditions. DNA microarray data of in vitro generated steady state
MPP, CDP, cDC and pDC and inﬂammatory GM-MPP, GM-DC and GM-TNF--DC  were
analyzed by principal component analysis (PCA) and hierarchical cluster analysisK.M. Seré et al. / European Journ
ardly affected by hyper-IL-6 indicating that GM-CSF/STAT5 sig-
aling is not antagonized by gp130 signaling.
M-CSF activates an inﬂammatory gene expression program in
PP
Previously we performed genome-wide gene expression anal-
sis of MPP, CDP, cDC and pDC (Felker et al., 2010). This analysis
evealed that genes important for DC development in steady state
onditions are already upregulated from MPP  to CDP, rendering
DP a DC-primed character. More and more evidence arises that
nﬂammatory mediators affect the developmental potential of stem
nd progenitor cells (Belyaev et al., 2010; Nagai et al., 2006). GM-
SF is considered as an inﬂammatory DC-poietin, giving rise to an
nﬂammatory type of DC (GM-DC) (Shortman and Naik, 2007). We
ow analyzed whether GM-CSF, when added in culture, imposes an
nﬂammatory signature on MPP. Such an inﬂammatory state might
kew DC development of MPP  towards GM-DC, and block steady
tate Flt3L-driven differentiation into cDC and pDC.
Global gene expression of cells cultured under steady state
onditions (MPP, CDP, cDC and pDC) or inﬂammatory conditions
GM-MPP and GM-DC) were compared by principal component
nalysis (PCA, Fig. 3A). Principal component 1 (PC1) clearly sep-
rates steady state DC (pDC and cDC) from inﬂammatory GM-DC.
nterestingly, this separation between the steady state and inﬂam-
atory condition is already revealed at the MPP  level (compare
PP  and GM-MPP), albeit less pronounced compared to DC. PC2
ositions progenitors in proximity and distinct from differentiated
DC, pDC and GM-DC.
Hierarchical cluster analysis was performed to reveal the simi-
arity between steady state MPP/CDP and inﬂammatory GM-MPP.
n a genome-wide gene expression level, steady state and inﬂam-
atory progenitors cluster together (Fig. 3B). Most distant are
M-DC which represent a separate branch in the hierarchical tree.
n conclusion, MPP  grown under inﬂammatory conditions contain
 gene expression pattern, which is already biased towards GM-DC
evelopment, as revealed by PCA.
Next we obtained a more detailed insight into the inﬂuence of
n inﬂammatory environment on MPP. To this end, gene expres-
ion data sets of GM-MPP were compared to those of MPP, cDC or
M-DC. These pair-wise comparisons generated a list of in total
318 genes, which were more than 2-fold differentially expressed
etween GM-MPP and MPP, GM-MPP and cDC, or GM-MPP and
M-DC. The genes were subjected to hierarchical cluster analysis
nd organized into 8 clusters (Fig. 4 and Table 1).
Clusters I and VI contain genes which show the same expres-
ion in steady state and inﬂammation. Cluster I comprises pan-DC
enes which are similarly expressed by cDC and GM-DC (Table 1).
his cluster includes several members of the Irf family, which are
nown to be important for DC development and function, such as
rf4, Irf8, Irf5 and Irf7. Cluster I also includes Cd83, Cd86, Icam1 and
HC-II, all involved in antigen presentation. Other genes in clus-
er I are chemokines Ccl5, Cxcl16 and Ccl22 and receptors Ptger4,
cr7, Il10ra, Ccr5. Cluster VI comprises several transcription fac-
ors associated with multipotency and non-DC lineages, like Gﬁ1,
fe2, Id1, Cebpa, Hoxa9, Myb, Gﬁ1b, Gata2, Lyl1 as well as other
ematopoietic stem and progenitor cell-related genes, like Prom1,
gf1r, Cxcr4, Csf3r, Pdgfrb. These genes are expressed at high level
n MPP  and GM-MPP and are down-regulated in cDC and GM-DC
pan-MPP, Table 1).
Clusters III and IV distinguish steady state MPP  and cDC from
nﬂammatory GM-MPP and GM-DC. Cluster III contains genes that
re strongly upregulated upon Flt3L-driven DC differentiation but
ot upon GM-CSF-induced differentiation, and are therefore cDC
peciﬁc (steady state DC, Table 1). This cluster includes transcrip-
ion factors, like Spib, Tcf4 and Bcl11a and CDP-related genes, like(A  and B, respectively). (A) PC1 (45% of all genes) distinguishes steady state from
inﬂammatory conditions, left and right, respectively, indicated by dashed lines. PC2
(27% of all genes) separates MPP  from DC, MPP indicated by a rectangle.
Cx3cr1 and Flt3. This suggests that the presence of GM-CSF inhibits
progression of MPP  into CDP, which is the ﬁrst step in DC commit-
ment under steady state conditions.
Cluster IV contains genes, which are GM-CSF-regulated as they
are expressed at a higher level in inﬂammatory GM-MPP and GM-
DC compared to steady state MPP  or cDC (Table 1). Genes include
several toll-like receptor (Tlr) family members (Tlr6, Tlr7, Tlr2 and
Tlr8) and myeloid lineage-associated genes, like Cebpb, Cd177,
Fcgr3, Cd68, Il4ra and Fcgr4. Cluster IV comprises also Csf2ra, Jak1
and Stat6, which might be involved in GM-CSF signaling.
Cluster II includes a set of DC-speciﬁc genes, which are already
expressed in inﬂammatory GM-MPP but not in steady state MPP
(non-MPP, Table 1). These genes comprise myeloid lineage related
genes, like Id2, Klf4, Maf, Jun, Irf2, Itgam.
Cluster V contains genes which are speciﬁc for GM-DC and
include chemotaxis-involved genes like Ccl2, Ccl17, Cxcr7, Cxcl3,
Ccl9, Ccl4, as well as several growth factors and cytokines and their
receptors, like Csf2rb, Igf2r, Pdgfc, Il1a, Tnfsf4, Pdgfa, Tgfbr1, Csf1,
Il15, Igf1.
GM-CSF contributes modestly to steady state DC develop-
ment and appears to be involved in the maintenance of DC
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Table  1
Genes differentially expressed between GM-MPP and MPP, cDC or GM-DC.
Cluster Number of genes Name Genes
I 325 pan-DC MHC-II, Cd83, Ptger4, Ccl5, Ccr7, Irf8, Irf4, Il10ra, Cxcl16, Cd86, Ccr5, Irf5, Ccl22, Irf7, Icam1
II 233 non-MPP Id2, Klf4, Maf, Jun, Irf2, Itgam
III 460 steady state DC Spib, Tcf4, Bcl11a, Cx3cr1, Flt3
IV  534 GM-CSF regulated Cd177, Cebpb, F
V  403 GM-DC Ccl2, Csf2rb, Igf
VI  801 pan-MPP Gﬁ1, Nfe2, Prom
Fig. 4. Impact of GM-CSF on gene expression pattern in MPP  and DC. Hierarchical
cluster analysis of gene expression in MPP, GM-MPP, cDC and GM-DC. Gene expres-
sion data of 3318 genes that were >2-fold differentially expressed between GM-MPP
and MPP, GM-MPP and cDC and GM-MPP and GM-DC are depicted in heatmap for-
mat. Blue color represents expression below median, red color represents expression
above median. Cluster I: pan-DC genes; Cluster II: non-MPP genes; Cluster III: cDC
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by RT-qPCR. From our work on CDP, we know that members ofenes; Cluster IV: GM-CSF-regulated genes; Cluster V: GM-DC genes; Cluster VI:
an-MPP genes.
rogenitors (Kingston et al., 2009). During inﬂammation, however,
ystemic levels of GM-CSF rise which can drive GM-DC develop-
ent (Shortman and Naik, 2007). Our gene expression data show
hat MPP  acquire a GM-DC primed transcription proﬁle in the pres-
nce of GM-CSF. At the MPP  level, GM-CSF inhibits expression of
enes involved in Flt3L steady state pDC and cDC development
cluster III). This notion is in agreement with the recent observation
hat GM-CSF/STAT5 signaling blocks steady state DC development
n vitro, in particular pDC development from Flt3+ DC precursors
Esashi et al., 2008; Gilliet et al., 2002). Furthermore, GM-CSF upreg-
lates expression of myeloid-related genes (clusters IV and II),
hich might indicate that GM-CSF induces development of mono-
ytes and further differentiation into GM-DC.cgr3, Tlr6, Tlr7, Csf2ra, Jak1, Cd68, Tlr2, Stat6, Tlr8, Il4ra, Fcgr4
2r, Ccl17, Pdgfc, Il1a, Tnfsf4, Cxcr7, Pdgfa, Cxcl3, Tgfbr1, Csf1, Il15, Ccl9, Ccl4, Igf1
1, Id1, Cebpa, Hoxa9, Myb, Gﬁ1b, Igf1r, Gata2, Cxcr4, Csf3r, Lyl1, Pdgfrb
Commitment of MPP to DC lineage is inﬂuenced by TGF-ˇ1
The cytokine TGF-1 is involved in a number of biological
processes, including hematopoiesis (Fortunel et al., 2000). The
inﬂuence of TGF-1 on hematopoietic progenitor cells is cell lin-
eage and context dependent. To investigate whether MPP/CDP
cultures are sensitive to TGF-1, cells were examined in a colony
forming assay. MPP  typically generate large colonies of differ-
ent lineages in semisolid medium containing SCF, IL-3, IL-6 and
Epo (Fig. 5A, left panel) (Felker et al., 2010). When TGF-1 was
added to the medium, colony formation was clearly affected. At
early time points after plating, the morphology of the colonies was
changed from a dense, immature type of colony to a more differ-
entiated, mature type of colony (Fig. 5A, right panel). To analyze
if TGF-1 affects MPP  and CDP maintenance, TGF-1 treatment of
MPP/CDP was  repeated in liquid culture. Flow cytometry indicated
that MPP  and CDP populations vanished after 4 days of TGF-1
treatment (2.5 ng/ml, Fig. 5B). Moreover, sustained TGF-1 treat-
ment induced apoptosis of TGF-1 sensitive cells (data not shown),
causing a reduction in total cell numbers (Fig. 5C). Flow cytometry
showed that the remaining cells in the TGF-1 treated culture were
enriched in myeloid cells. Almost 30% of the cells stained positive
for Gr-1, CD115 and CD11b while in the absence of TGF-1 cultures
contained less than 10% of Gr-1+ CD115+ CD11b+ cells (Fig. 5D).
These data are in agreement with our previous observation that
sustained TGF-1 treatment induces apoptosis in MPP  and CDP
(Felker et al., 2010). TGF-1 can induce apoptosis in TGF-1 sen-
sitive cells (Fortunel et al., 2000). As a consequence, in MPP/CDP
cultures TGF-1 supports the development of myeloid cells, pos-
sibly because they are less sensitive to TGF-1. Moreover, the
inﬂuence of TGF-1 on hematopoietic cells is lineage dependent
(Fortunel et al., 2000). A recent study showed different activities
of TGF-1 on myeloid-biased versus lymphoid-biased stem cells
(Challen et al., 2010). TGF-1 stimulates myeloid-biased stem cells
and inhibits lymphoid-biased cells. Such discriminating impact of
TGF-1 on myeloid and lymphoid lineages is endorsed by other
studies, for example TGF-1 blocks pro-B cell growth and survival
(Kee et al., 2001).
The impact of TGF-1 on DC development is best docu-
mented for LC, as the epidermis of TGF-1 deﬁcient mice lacks
LC (Borkowski et al., 1996; Strobl and Knapp, 1999). Recently we
showed that TGF-1 also affects the growth of other DC subsets
(Felker et al., 2010). We  observed that TGF-1 enhances DC differ-
entiation from DC-committed progenitors (CDP) in vitro. Moreover,
we showed that TGF-1 inﬂuences DC subset speciﬁcation toward
cDC by inducing a cDC-related gene expression program. An inﬂu-
ence of TGF-1 on DC lineage commitment has not been reported
so far. Here we  investigated whether TGF-1 affects commitment
of MPP  to DC lineage.
To this end, MPP  were obtained by cell sorting and treated
with TGF-1 for 0, 4, 8, 12 or 24 h. Expression of DC-lineage afﬁl-
iated genes and of known TGF-1 target genes was evaluatedthe Id transcription factor family are TGF-1 target genes in DC-
committed cells (Felker et al., 2010). In MPP, however, the effect
of TGF-1 on Id expression was moderate. Id1 expression was
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Fig. 5. TGF-1 impacts on MPP/CDP cultures. (A) Bone marrow cells were ampliﬁed
as  in Fig. 1 for 8 days. 2500 cells were plated in semisolid methylcellulose containing
SCF, IL-3, IL-6, Epo, transferrin and insulin in the presence or absence of TGF-1
(10 ng/ml). After 3 days, colonies were analyzed. (B and C) Bone marrow cells were
grown as in (A) for 8 days, and cultured for an additional 4 days in the presence
or  absence of TGF-1 (2.5 ng/ml). (B) Cells were stained for c-kit, Flt3, Gr-1 and
CD115 and analyzed by ﬂow cytometry as in Fig. 1. (C) Total cell numbers with and
without TGF-1 (2.5 ng/ml, 4 days) were determined and are depicted. (D) Same
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Fig. 6. TGF-1 target genes in steady state and inﬂammatory MPP. Bone marrow
cells were ampliﬁed as in Fig. 1. After 7 days of culture, MPP  were sorted as c-kithi
Flt3−/lo CD11c− cells and cultured further with the same growth factors, referred to
as  steady state MPP. Alternatively, bone marrow cells were cultured with growth
factors as above but supplemented with 20 U/ml GM-CSF, referred to as inﬂamma-
tory MPP (GM-MPP) (Hieronymus et al., 2005). MPP  and GM-MPP were treated with
TGF-1 (10 ng/ml) for increasing periods of time, as indicated. TGF-1 induced genes
were analyzed by RT-qPCR and expression levels (Ct values relative to GAPDH)ells as in (B) were analyzed for myeloid markers Gr-1, CD115 and CD11b. Numbers
f Gr-1+ CD115+ CD11b+ monocytic cells were determined and are depicted (mean
alues ± SD of 3 experiments).
ot changed in response to TGF-1, while Id2 and Id3 showed a
mall increase in expression (Fig. 6, upper panel). The Irf family
f transcription factors comprises another set of genes, which are
mportant for hematopoiesis in general and for DC development
nd function in particular (Tamura et al., 2008). Moreover, in CDP
nd DC, TGF-1 affects the expression of several Irf genes (Felker
t al., 2010; Ju et al., 2007). Therefore we analyzed Irf-4 and Irf-8
xpression in response to TGF-1 in MPP. Irf-4 showed a moderate
ncrease in expression while Irf-8 was strongly upregulated by TGF-
1 (Fig. 6, upper panel). Upregulation of Irf-8 was  fast and sustained
or the entire period of TGF-1 treatment. As expected, Smad7 was
ighly upregulated as soon as 4 h after the start of TGF-1 treat-
ent. Smad7 is a well-known TGF-1 target gene and was  used
ere as a control gene to conﬁrm the efﬁcient response of MPP  to
GF-1.
As steady state DC development is known to be dependent on
he Flt3L/Flt3 pathway and DC-committed progenitors are all Flt3
ositive, we wondered whether TGF-1 would affect Flt3 expres-
ion in MPP. Interestingly, Flt3 was strongly induced in response to
GF-1. Upregulation of Flt3 was maximal after 8 h of treatment,are represented in heatmap format. Red: high expression, blue: low expression, as
in  Fig. 4. One representative experiment of 4 is shown.
and the high expression level was maintained during the following
16 h. As Irf-8 and Flt3 are early responders they might be direct TGF-
1 target genes, which would be in agreement with the observation
in human DC (Ju et al., 2007).
MPP are upstream of CDP and gene expression proﬁling of MPP
and CDP revealed a DC-primed gene expression signature in CDP
(Felker et al., 2010). Amongst the genes that are upregulated from
MPP  to CDP – and therefore might play a role in DC lineage com-
mitment – are Flt3 and Irf-8. Here we show that these two genes
are strongly induced by TGF-1 in MPP, which would suggest that
TGF-1 induces DC commitment in MPP. The observation that Id
factors are only modestly affected by TGF-1 in MPP, whereas in
CDP they are strong responders (Felker et al., 2010), indicates that
the TGF-1 target gene repertoire is different in MPP  and CDP. It
can be reasoned that factors important for DC lineage commitment
are target genes in MPP, whereas genes important for DC subset
speciﬁcation are affected in CDP. Further genome-wide analysis is
needed to support this assumption.
As we hypothesize that TGF-1 promotes steady state DC com-
mitment in MPP, we next asked how GM-MPP, grown under
inﬂammatory conditions, respond to TGF-1. As discussed above,
GM-MPP contain a GM-CSF-primed gene expression signature.
Moreover, several genes important for steady state DC differ-
entiation, including Flt3, were not upregulated during GM-DC
development (Fig. 4, cluster III, Table 1). Therefore we evaluated
whether TGF-1 treatment of GM-MPP might reinforce a steady
state CDP-like gene expression program.
GM-MPP were treated with TGF-1 for 4, 8, 16 or 24 h or left
untreated. Gene expression was analyzed for the same set of genes
that were analyzed in TGF-1-treated MPP. Upregulation of Smad7
upon TGF-1 treatment indicated that GM-MPP were responsive
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Fig. 7. Schematic representation depicting the impact of external factors on DC
lineage commitment and differentiation. Mouse bone marrow cells were grown
with SCF, Flt3L, IGF-1 and hyper-IL-6 to obtain MPP  and CDP, and their differentiated
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Brogeny pDC, cDC and GM-DC, as indicated. The activity of cytokines on MPP  to
DP progression and DC differentiation is indicated. Cytokines with promoting and
nhibiting activity are depicted in green and red, respectively.
o TGF-1. Id1, Id2 and Irf-4 showed a slight increase in expression
hich was less than 2-fold (Fig. 6, lower panel). Irf-8 was  upreg-
lated more than 2-fold, conﬁrming that Irf-8 is a TGF-1 target
ene also in GM-MPP (Ju et al., 2007). Id3 and, interestingly, Flt3
ere not upregulated, but rather showed a decrease in expression
n response to TGF-1.
It is tempting to speculate that under inﬂammatory conditions
lt3 expression is blocked, thereby prohibiting MPP  progression
nto CDP, which is necessary for steady state DC development.
GF-1 does not erase this inﬂammatory imprint and does not
esuscitate steady state DC development.
Taken together, in this study we show the impact of further fac-
ors promoting or inhibiting DC commitment and differentiation.
yper-IL-6/gp130 signaling promotes MPP  expansion and thus
ffects the balance of MPP  commitment into CDP and further devel-
pment into DC (Fig. 7). Additionally, TGF-1 signaling appears
o inﬂuence the MPP-CDP transition by upregulating DC-afﬁliated
enes such as Flt3 and Irf-8. We  hypothesize that increased Flt3
xpression might confer a higher susceptibility to Flt3L and thus
C development. GM-CSF impacts on MPP  and induces an inﬂam-
atory gene expression signature, including down-regulation of
enes important for steady state DC development. This emphasizes
he context dependent activity of cytokines under steady state and
nﬂammation, respectively.
cknowledgements
We thank C. Becker and J. Fleischer for assistance with experi-
ents, Zi Wang for help during the initial phase of this study and M.
ristov for cell sorting. This work was supported by funding from
FG/SFB542.
eferences
udet, J., Miller, C.L., Rose-John, S., Piret, J.M., Eaves, C.J., 2001. Distinct role of gp130
activation in promoting self-renewal divisions by mitogenically stimulated
murine hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 98, 1757–1762.
uffray, C., Fogg, D.K., Narni-Mancinelli, E., Senechal, B., Trouillet, C., Saederup, N.,
Leemput, J., Bigot, K., Campisi, L., Abitbol, M.,  Molina, T., Charo, I., Hume, D.A.,
Cumano, A., Lauvau, G., Geissmann, F., 2009. CX3CR1+ CD115+ CD135+ com-
mon  macrophage/DC precursors and the role of CX3CR1 in their response to
inﬂammation. J. Exp. Med. 206, 595–606.
elyaev, N.N., Brown, D.E., Diaz, A.I., Rae, A., Jarra, W.,  Thompson, J., Langhorne,
J.,  Potocnik, A.J., 2010. Induction of an IL7-R(+)c-Kit(hi) myelolymphoid pro-
genitor critically dependent on IFN-gamma signaling during acute malaria. Nat.
Immunol. 11, 477–485.
enjamini, Y., Hochberg, Y., 1995. Controlling the false discovery rate – a practical
and  powerful approach to multiple testing. J. R. Stat. Soc. Ser. B: Methodol. 57,
289–300.
orkowski, T.A., Letterio, J.J., Farr, A.G., Udey, M.C., 1996. A role for endogenous trans-
forming growth factor beta 1 in Langerhans cell biology: the skin of transforming
growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J. Exp.
Med. 184, 2417–2422.
rawand, P., Fitzpatrick, D.R., Greenﬁeld, B.W., Brasel, K., Maliszewski, C.R., De
Smedt, T., 2002. Murine plasmacytoid pre-dendritic cells generated from Flt3ell Biology 91 (2012) 515– 523
ligand-supplemented bone marrow cultures are immature APCs. J. Immunol.
169, 6711–6719.
Challen, G.A., Boles, N.C., Chambers, S.M., Goodell, M.A., 2010. Distinct hematopoietic
stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell 6,
265–278.
Cisse, B., Caton, M.L., Lehner, M.,  Maeda, T., Scheu, S., Locksley, R., Holmberg, D.,
Zweier, C., den Hollander, N.S., Kant, S.G., Holter, W.,  Rauch, A., Zhuang, Y.,
Reizis, B., 2008. Transcription factor E2-2 is an essential and speciﬁc regulator
of  plasmacytoid dendritic cell development. Cell 135, 37–48.
Esashi, E., Wang, Y.H., Perng, O., Qin, X.F., Liu, Y.J., Watowich, S.S., 2008. The signal
transducer STAT5 inhibits plasmacytoid dendritic cell development by sup-
pressing transcription factor IRF8. Immunity 28, 509–520.
Felker, P., Sere, K., Lin, Q., Becker, C., Hristov, M.,  Hieronymus, T., Zenke, M.,  2010.
TGF-beta1 accelerates dendritic cell differentiation from common dendritic cell
progenitors and directs subset speciﬁcation toward conventional dendritic cells.
J.  Immunol. 185, 5326–5335.
Fischer, M.,  Goldschmitt, J., Peschel, C., Brakenhoff, J.P., Kallen, K.J., Wollmer, A.,
Grotzinger, J., Rose-John, S.I., 1997. A bioactive designer cytokine for human
hematopoietic progenitor cell expansion. Nat. Biotechnol. 15, 142–145.
Fortunel, N.O., Hatzfeld, A., Hatzfeld, J.A., 2000. Transforming growth factor-beta:
pleiotropic role in the regulation of hematopoiesis. Blood 96, 2022–2036.
Geissmann, F., Manz, M.G., Jung, S., Sieweke, M.H., Merad, M.,  Ley, K., 2010. Devel-
opment of monocytes, macrophages, and dendritic cells. Science 327, 656–661.
Gilliet, M.,  Boonstra, A., Paturel, C., Antonenko, S., Xu, X.L., Trinchieri, G., O’Garra,
A., Liu, Y.J., 2002. The development of murine plasmacytoid dendritic cell pre-
cursors is differentially regulated by FLT3-ligand and granulocyte/macrophage
colony-stimulating factor. J. Exp. Med. 195, 953–958.
Hacker, C., Kirsch, R.D., Ju, X.S., Hieronymus, T., Gust, T.C., Kuhl, C., Jorgas, T., Kurz,
S.M., Rose-John, S., Yokota, Y., Zenke, M.,  2003. Transcriptional proﬁling identi-
ﬁes Id2 function in dendritic cell development. Nat. Immunol. 4, 380–386.
Heinz, L.X., Platzer, B., Reisner, P.M., Jorgl, A., Taschner, S., Gobel, F., Strobl, H.,
2006. Differential involvement of PU.1 and Id2 downstream of TGF-beta1 during
Langerhans-cell commitment. Blood 107, 1445–1453.
Hieronymus, T., Gust, T.C., Kirsch, R.D., Jorgas, T., Blendinger, G., Goncharenko, M.,
Supplitt, K., Rose-John, S., Muller, A.M., Zenke, M.,  2005. Progressive and con-
trolled development of mouse dendritic cells from Flt3+CD11b+ progenitors in
vitro. J. Immunol. 174, 2552–2562.
Hildner, K., Edelson, B.T., Purtha, W.E., Diamond, M.,  Matsushita, H., Kohyama,
M., Calderon, B., Schraml, B.U., Unanue, E.R., Diamond, M.S., Schreiber, R.D.,
Murphy, T.L., Murphy, K.M., 2008. Batf3 deﬁciency reveals a critical role
for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322,
1097–1100.
Inaba, K., Inaba, M.,  Romani, N., Aya, H., Deguchi, M.,  Ikehara, S., Muramatsu, S., Stein-
man, R.M., 1992. Generation of large numbers of dendritic cells from mouse
bone marrow cultures supplemented with granulocyte/macrophage colony-
stimulating factor. J. Exp. Med. 176, 1693–1702.
Johnson, W.E., Li, C., Rabinovic, A., 2007. Adjusting batch effects in microarray
expression data using empirical Bayes methods. Biostatistics 8, 118–127.
Ju, X.S., Ruau, D., Jantti, P., Sere, K., Becker, C., Wiercinska, E., Bartz, C., Erd-
mann, B., Dooley, S., Zenke, M.,  2007. Transforming growth factor beta1
up-regulates interferon regulatory factor 8 during dendritic cell development.
Eur. J. Immunol. 37, 1174–1183.
Kee, B.L., Rivera, R.R., Murre, C., 2001. Id3 inhibits B lymphocyte progenitor growth
and survival in response to TGF-beta. Nat. Immunol. 2, 242–247.
Kingston, D., Schmid, M.A., Onai, N., Obata-Onai, A., Baumjohann, D., Manz, M.G.,
2009. The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell
homeostasis. Blood 114, 835–843.
Kondo, M., Scherer, D.C., Miyamoto, T., King, A.G., Akashi, K., Sugamura, K., Weiss-
man,  I.L., 2000. Cell-fate conversion of lymphoid-committed progenitors by
instructive actions of cytokines. Nature 407, 383–386.
Laouar, Y., Welte, T., Fu, X.Y., Flavell, R.A., 2003. STAT3 is required for Flt3L-dependent
dendritic cell differentiation. Immunity 19, 903–912.
Liu, K., Victora, G.D., Schwickert, T.A., Guermonprez, P., Meredith, M.M., Yao, K.,  Chu,
F.F., Randolph, G.J., Rudensky, A.Y., Nussenzweig, M.,  2009. In vivo analysis of
dendritic cell development and homeostasis. Science 324, 392–397.
McKenna, H.J., Stocking, K.L., Miller, R.E., Brasel, K., De Smedt, T., Maraskovsky,
E.,  Maliszewski, C.R., Lynch, D.H., Smith, J., Pulendran, B., Roux, E.R., Teepe,
M., Lyman, S.D., Peschon, J.J., 2000. Mice lacking ﬂt3 ligand have deﬁcient
hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and nat-
ural killer cells. Blood 95, 3489–3497.
Merad, M., Manz, M.G., 2009. Dendritic cell homeostasis. Blood 113, 3418–3427.
Nagai, Y., Garrett, K.P., Ohta, S., Bahrun, U., Kouro, T., Akira, S., Takatsu, K., Kin-
cade, P.W., 2006. Toll-like receptors on hematopoietic progenitor cells stimulate
innate immune system replenishment. Immunity 24, 801–812.
Naik, S.H., Metcalf, D., van Nieuwenhuijze, A., Wicks, I., Wu,  L., O’Keeffe, M.,  Short-
man, K., 2006. Intrasplenic steady-state dendritic cell precursors that are distinct
from monocytes. Nat. Immunol. 7, 663–671.
Naik, S.H., Proietto, A.I., Wilson, N.S., Dakic, A., Schnorrer, P., Fuchsberger, M., Lahoud,
M.H., O’Keeffe, M.,  Shao, Q.X., Chen, W.F., Villadangos, J.A., Shortman, K., Wu,  L.,
2005. Cutting edge: generation of splenic CD8+ and CD8− dendritic cell equiv-
alents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J. Immunol.
174, 6592–6597.
Naik, S.H., Sathe, P., Park, H.Y., Metcalf, D., Proietto, A.I., Dakic, A., Carotta, S., O’Keeffe,
M., Bahlo, M.,  Papenfuss, A., Kwak, J.Y., Wu,  L., Shortman, K., 2007. Development
of  plasmacytoid and conventional dendritic cell subtypes from single precursor
cells derived in vitro and in vivo. Nat. Immunol. 8, 1217–1226.
al of C
O
O
P
R
R
R
S
SK.M. Seré et al. / European Journ
nai, N., Obata-Onai, A., Schmid, M.A., Ohteki, T., Jarrossay, D., Manz, M.G., 2007.
Identiﬁcation of clonogenic common Flt3+M-CSFR+ plasmacytoid and conven-
tional dendritic cell progenitors in mouse bone marrow. Nat. Immunol. 8,
1207–1216.
nai, N., Obata-Onai, A., Tussiwand, R., Lanzavecchia, A., Manz, M.G., 2006. Acti-
vation of the Flt3 signal transduction cascade rescues and enhances type
I  interferon-producing and dendritic cell development. J. Exp. Med. 203,
227–238.
eters, M.,  Schirmacher, P., Goldschmitt, J., Odenthal, M., Peschel, C., Fattori,
E.,  Ciliberto, G., Dienes, H.P., Meyer zum Buschenfelde, K.H., Rose-John,
S.,  1997. Extramedullary expansion of hematopoietic progenitor cells
in  interleukin (IL)-6-sIL-6R double transgenic mice. J. Exp. Med. 185,
755–766.
akemann, T., Niehof, M.,  Kubicka, S., Fischer, M.,  Manns, M.P., Rose-John, S.,
Trautwein, C., 1999. The designer cytokine hyper-interleukin-6 is a potent acti-
vator of STAT3-dependent gene transcription in vivo and in vitro. J. Biol. Chem.
274, 1257–1266.
athinam, C., Geffers, R., Yucel, R., Buer, J., Welte, K., Moroy, T., Klein, C., 2005. The
transcriptional repressor Gﬁ1 controls STAT3-dependent dendritic cell devel-
opment and function. Immunity 22, 717–728.
eis e Sousa, C., 2006. Dendritic cells in a mature age. Nat. Rev. Immunol. 6, 476–483.
allusto, F., Lanzavecchia, A., 1994. Efﬁcient presentation of soluble antigen bycultured human dendritic cells is maintained by granulocyte/macrophage
colony-stimulating factor plus interleukin 4 and downregulated by tumor necro-
sis factor alpha. J. Exp. Med. 179, 1109–1118.
chiavoni, G., Mattei, F., Sestili, P., Borghi, P., Venditti, M.,  Morse III, H.C., Belardelli,
F.,  Gabriele, L., 2002. ICSBP is essential for the development of mouse type Iell Biology 91 (2012) 515– 523 523
interferon-producing cells and for the generation and activation of CD8alpha(+)
dendritic cells. J. Exp. Med. 196, 1415–1425.
Schotte, R., Nagasawa, M.,  Weijer, K., Spits, H., Blom, B., 2004. The ETS transcription
factor Spi-B is required for human plasmacytoid dendritic cell development. J.
Exp.  Med. 200, 1503–1509.
Shortman, K., Naik, S.H., 2007. Steady-state and inﬂammatory dendritic-cell devel-
opment. Nat. Rev. Immunol. 7, 19–30.
Steinman, R.M., Banchereau, J., 2007. Taking dendritic cells into medicine. Nature
449, 419–426.
Strobl, H., Knapp, W.,  1999. TGF-beta1 regulation of dendritic cells. Microbes Infect.
1,  1283–1290.
Sui, X., Tsuji, K., Tanaka, R., Tajima, S., Muraoka, K., Ebihara, Y., Ikebuchi, K., Yasukawa,
K.,  Taga, T., Kishimoto, T., et al., 1995. gp130 and c-Kit signalings synergize for
ex  vivo expansion of human primitive hemopoietic progenitor cells. Proc. Natl.
Acad. Sci. U.S.A. 92, 2859–2863.
Tamura, T., Tailor, P., Yamaoka, K., Kong, H.J., Tsujimura, H.,  O’Shea, J.J.,
Singh, H., Ozato, K., 2005. IFN regulatory factor-4 and -8 govern dendritic
cell subset development and their functional diversity. J. Immunol. 174,
2573–2581.
Tamura, T., Yanai, H., Savitsky, D., Taniguchi, T., 2008. The IRF family tran-
scription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26,
535–584.Varol, C., Landsman, L., Fogg, D.K., Greenshtein, L., Gildor, B., Margalit, R., Kalchenko,
V., Geissmann, F., Jung, S., 2007. Monocytes give rise to mucosal, but not splenic,
conventional dendritic cells. J. Exp. Med. 204, 171–180.
Zenke, M.,  Hieronymus, T., 2006. Towards an understanding of the transcription
factor network of dendritic cell development. Trends Immunol. 27, 140–145.
